Clinical trial
Gene Expression During Chemotherapy in Patients With Newly Diagnosed Acute…
NCT00156299 · Rutgers, The State University of New Jersey, Other · Terminated
Key facts
| NCT number | NCT00156299 |
|---|---|
| Title | Gene Expression During Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Choline Magnesium Trisalicylate |
| Official title | A Pilot Study of Nuclear Factor-kappa B (NFkB) Inhibition During Induction Chemotherapy for Patients With Acute Myelogenous Leukemia (AML) |
| Lead sponsor | Rutgers, The State University of New Jersey, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | choline magnesium trisalicylate, Dexamethasone |
| Enrollment | 15 |
| Start date | Mar 1, 2003 |
| Primary completion | Jul 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Sep 12, 2005 |
| Last update posted | Nov 19, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: